Donate

*Does Avodart (Dutasteride) Allow Men on Intermittent Androgen Therapy To Have A Longer “Off Period”?

Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month [...]

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

Looking Forward Towards the Future – Zytiga or Xtandi First After Provenge

What will happen when enzalutamide (Xtandi) is approved for use in advanced prostate cancer in the disease stage prior to chemotherapy (that is if it is approved)?  Already occupying this space and already approved by the FDA is both Provenge and abiraterone (Zytiga).  Where will Xtandi fit in? Until we have a lot more data, [...]

Results of the Earl Access Trial of Enzalutamide Leading to the FDA Approval

Malecare was actively involved, along with its partners, in setting up the early access trial for enzalutamide (Xtandi).  The trial was conducted after the final Phase 3 AFFIRM trial that was eventually used to obtain FDA approval had been stopped, but before the FDA and received the final submission of the data.  Given the significant [...]

ASCO 2014: Combining Advanced Hormone Therapies (Zytiga & Xtandi) Shows Promise for Men with Advanced Prostate Cancer

In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy.  This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga)  drove down testosterone levels and appeared [...]

A Surprising Biochemical Response to Ketoconazole In Post-Chemotherapy mCRPC Men When Compared to the Zytiga Trial Results

It has always been assumed that Ketoconazole, when used for the treatment of men with metastatic castration resistant prostate cancer (mCRPC), would not be as potent as abiraterone (Zytiga), but there has never been any head to head comparison to demonstrate this assumption! Ketoconazole is a less potent inhibitor of the CYP-17 enzyme, the mode [...]

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT.  However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

An Early Peek At the Phase III PREVAIL Trial of Enzalutamide (Xtandi) Results – Good For Prostate Cancer

An important update from the phase III PREVAIL study (Xtandi in the pre-chemotherapy stage) was released thsi evening (actually yesterday evening) in advance of a formal presentation this Thursday at ASCO GU. The news is good, no the news is great. Last November the trial of Xtandi in men with metastatic castrate resistant prostate cancer [...]

A First Victory in Our Fight Against Fail First Therapy – Thanking Health Partners in Minnesota for Their Concern for Men with Advanced Prostate Cancer

Fail First Therapy or Step Therapy has been a topic I have written about in prior posts. It is my considered opinion that as it works its way into the treatment protocols for advanced prostate cancer it will have nothing but a very negative result for our health and longevity. What is Fail First Therapy [...]

Great Video Worth Spending the 9 Minutes Required Discussing Provenge and the Use of Zytiga (Along with Prednisone)

OncLive Peer Exchange has put out a video about the issues that most concern many of us surrounding the use of Provenge (Sipuleucel-T).   The video is a 9 minute discussion with Drs. Raoul Concepcion (moderator), Leonard Gomella, Lawrence Karsh, Evan Yu and Mark Scholtz.  They examine the concern that so many men with advanced prostate [...]

Go to Top